Introduction
Inflammatory bowel disease (IBD), encompassing Crohn’s disease (CD) and ulcerative colitis (UC), is characterized by chronic inflammation affecting the gastrointestinal tract and extraintestinal organs. The etiology of IBD is multifactorial, involving genetic, immunological, and environmental factors, with significant genetic predisposition indicated by over 200 identified loci associated with the disease. Despite advancements in understanding the genetic basis of IBD, clinical management remains challenging due to heterogeneity in disease presentation and variable treatment responses. Current therapies, including 5-aminosalicylates and biologics, are not universally effective, highlighting the urgent need for reliable biomarkers to predict therapeutic responses. This study investigates the potential role of interferon regulatory factor 5 (IRF5) in IBD pathogenesis, particularly in UC.
Aims & Methods
We conducted a systematic analysis of colon biopsies from adult patients diagnosed with UC and non-IBD controls. Immunostaining was performed to assess IRF5 expression in colonic tissues, and statistical analyses were conducted to evaluate the correlation between IRF5-positive cell counts, disease activity, and inflammatory markers such as calprotectin
Results
Our analysis revealed a significant increase in IRF5-positive macrophage-like cells in the inflamed mucosa of IBD patients compared to healthy controls. The number of IRF5-positive cells correlated positively with disease activity and calprotectin levels, indicating that higher IRF5 expression is associated with increased inflammation.
Conclusion
This study establishes a significant correlation between IRF5 expression and disease activity in UC, suggesting that IRF5 may play a crucial role in the inflammatory processes associated with the disease. The findings propose IRF5 as a novel biomarker for therapeutic intervention in IBD. Further research is warranted to elucidate the exact mechanisms by which IRF5 contributes to IBD pathogenesis and to evaluate the therapeutic potential of targeting this pathway in clinical settings.
References
Anderson CA, Boucher G, Lees CW, Franke A, D'Amato M, Taylor KD, et al. Meta-analysis identifies 29 additional ulcerative colitis risk loci, increasing the number of confirmed associations to 47. Nat Genet. 2011;43(3):246-52.
Dideberg V, Kristjansdottir G, Milani L, Libioulle C, Sigurdsson S, Louis E, et al. An insertion-deletion polymorphism in the interferon regulatory Factor 5 (IRF5) gene confers risk of inflammatory bowel diseases. Hum Mol Genet. 2007;16(24):3008-16.
Yang Y, Zhang C, Jing D, He H, Li X, Wang Y, et al. IRF5 Acts as a Potential Therapeutic Marker in Inflammatory Bowel Diseases. Inflammatory bowel diseases. 2021;27(3):407-17.
Troncone E, Laudisi F, Di Fusco V, Dinallo V, De Simone E, Monteleone I, et al. Interferon Regulatory Factor 5 Expressing Cells infiltrate Lamina Propria of IBD Patients and produce inflammatory Cytokines. Digestive and Liver Disease. 2017;49(s2):e73-e223.
Disclosure
Lecturing fees from Immndiagnostik, MSD, Janssen, Takeda, Abbvie, consultancy fees from Vifor Pharma and Takeda